



IMMUNOPRECISE ANTIBODIES

Decoding life's language: The ChatGPT of genomics

April 2023 | NASDAQ:IPA

HUB of Biotherapeutic Intelligence™

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Further information on risks and uncertainties may be found in the Company’s Management Discussion & Analysis which may be obtained from SEDAR at www.sedar.com and SEC at www.sec.gov.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Welcome Revolutionizing drug discovery with LENS^{ai}

IPA is an AI-driven technology company
at the forefront of genomic data analysis.

LENS^{ai}™ Integrated Intelligence Technology,
powered by our patented HYFT™ technology,
revolutionizes researchers' understanding and
analysis of omic data, leading to groundbreaking
discoveries and innovations in pharmaceuticals
and biotechnology.

Unlocking genomic insights with HYFT™ technology

The power of HYFTs

Designed to address the complex challenges faced by researchers in the field of drug discovery. HYFTs make it effortless to analyze massive amounts of biological data, producing scalable actionable insights revealing new discoveries with speed and accuracy.

First-in-class patented AI platform



Accelerating
new avenues for
pharmaceutical discovery
and research.

Wide-range of applications in genomics & biotechnology

The first technology
integrating diverse
genetic data and
providing scalable
insight into: genomic
sequence, structure,
function.

Sequence:
Multi-omics,
RNA, DNA &
Proteins

Structure:
Alpha fold,ESM-2,
Rosetta fold,
Cryo-EM,
Crystallography

NLP-based:
Patents,
Peer-reviewed
Literature,
Clinical trials



The possibilities are endless: more LENS^{ai} applications

Disruptive AI-driven biotherapeutic discovery potential

- Sequence similarity search and classification
- *De novo* sequence generation
- Integration of multi-omics data
- Benchmarking potential candidates
- Discover hidden candidates

Allowing unprecedented insight, accuracy, speed and efficiency.



Accelerating medical research and innovation

Our powerful technology is at the forefront of healthcare innovation, accelerating drug discovery through scalable data visualization and insights. Rapidly identify novel therapeutic targets and life-changing drug candidates, while powering personalized medicine for patients. **Join us in revolutionizing healthcare and improving lives globally.**

Our mission: is to reduce the risk, time, and cost associated with antibody discovery and drug development.

HYFTs insight represents months to years' worth of traditional research.


ENGINEERED for the biotherapeutic RACE



Capitalizing on a rapidly growing market

Market opportunities and growth potential


Genomics research, antibody discovery and personalized healthcare market is growing rapidly, presenting significant opportunities. Growth is further fueled by expanding use of LENS^{ai} in partnerships with top pharmaceutical firms and academic institutions.



Global biotechnology market

Poised to grow at a noteworthy CAGR of 8.7% from 2023 to 2030. Bio-informatics subset CAGR growth is 12.6%.¹

1. <https://www.precedenceresearch.com/biotechnology-market>



Built for the undiscovered

AI and genomics — working together to pave the way for a healthier future.

Scaling for the antibody era

The majority of the human genome is yet to be explored for potential drug candidates.

Out of over **20,000** proteins encoded in the human genome, less than **10%** of the druggable proteins are currently targeted by FDA-approved drugs.¹

1. <https://commonfund.nih.gov/idg/overview>



IpA

Our competitive edge:

Patented HYFT Technology & strong IP

We have a strong intellectual property portfolio protecting our core technologies and a highly experienced team of experts in life sciences and AI, ensuring that we remain at the cutting edge of biotherapeutic innovation.

The HUB of Biotherapeutic Intelligence™

Where we rank:

Clients: 80% of
top 20 pharma

Robust end-to-end discovery,
development and manufacturing
services with individualized
access to best-in-class AI
algorithms

#1 ranked CRO

Acclaimed by independent
company Roots Analysis.¹

1. ROOTS 2022, Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; pp.118

High-quality lab data fuels LENS^{ai}'s HYFT-based growth



Industry-leading research and continuous data enrichment drive innovation

- **Unique advantage**
LENS^{ai}'s exceptional growth powered by HYFTs and AI integration
- **Wet lab excellence**
Premium, comprehensive data enriches HYFTs for LENS^{ai}'s continuous refinement
- **LENS^{ai} AI platform**
Rapid, ongoing improvement by leveraging enriched HYFTs
- **Synergy & success**
Accelerated discovery and enhanced accuracy through data-driven HYFTs
- **Impact**
Cutting-edge solutions delivering unrivaled value to patients and partners



Investing in the future of genomics

IPA's diversified revenue stream

Equity in
diverse
therapeutic
assets


Accelerated
drug
development
for clients

Targeting new
diseases and
untapped
markets

Strategic
partnerships and
licensing
opportunities

Fee-for-service
work

Future revenue
stream: Omic
data organization,
management,
and analysis



At-A-Glance

Corporate profile



IPA (ImmunoPrecise Antibodies Ltd.) is an AI-driven biotherapeutic research and technology company focused on accelerating the discovery of novel medical treatments. Leveraging cutting-edge AI tools and a dedicated team of experts, IPA excels at connecting different types of biological information to identify innovative therapeutic targets. The company operates with a strong financial position, carrying no debt.

Capital Structure (all values in CAD unless otherwise noted) (NASDAQ: IPA)

SHARES DATA, 2021 (as of March 31, 2023)

Shares Outstanding	25,050,260
Share Price (USD)	\$2.77
Market Cap (USD)	\$69,389,220

WARRANTS (as of January 31, 2023)

Balance	Weighted Average Exercise Price	Weighted Average Life Remaining (Years)	Future Cash Opportunity
130,111 ⁽¹⁾	\$16.81	3.01	\$2.2 million

(1) Price and cash value stated in USD

BALANCES (as of January 31, 2023)

Cash on Hand	\$11.4 million
--------------	----------------

OPTIONS (as of January 31, 2023)

	Balance	Weighted Average Exercise Price	Weighted Average Life Remaining (Years)
Exercisable	1,229,519	\$8.75	2.25
Unvested	202,729	\$7.52	3.94
Total	1,432,248	\$8.58	2.49



IpA

Join us: transform genomics
& shape a healthier future

Thank you

HUB of Biotherapeutic Intelligence™

<http://www.ipatherapeutics.com/> | NASDAQ:IPA